US FDA reviewing mortality data from Eprex stroke study
This article was originally published in Scrip
Executive Summary
Mortality results from a German stroke study may warrant a re-examination of ongoing trials of erythropoiesis-stimulating agents (ESAs) for potential neuroprotective effects, the US FDAsaid.